Stay updated on Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial
Sign up to get notified when there's something new on the Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial page.

Latest updates to the Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded two editorial notes: PubMed-derived publications may not all be about the study, and the page now shows revision v3.3.2; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check17 days agoChange DetectedExpanded results section now includes granular safety data (TEAEs/SAEs by SOC and PT) for 1-year follow-up and the change from baseline in LV ejection fraction, across dosing cohorts.SummaryDifference15%

- Check39 days agoChange DetectedExternal reference links were added to the Study Results page, including PubMed articles (40753271, 40583275, 40583273, 40579547) and government information sites (hhs.gov, nih.gov, nlm.gov, ncbi.nlm.gov, usa.gov).SummaryDifference0.2%

- Check60 days agoChange Detected- Added a government funding lapse notice with operating status guidance and a link to cc.nih.gov and opm.gov. - Updated version from v3.1.0 to v3.2.0.SummaryDifference2%

- Check68 days agoChange DetectedVersion bump: replacing v3.0.2 with v3.1.0 in the page metadata.SummaryDifference0.0%

- Check75 days agoChange DetectedTwo new references about fordadistrogene movaparvovec in Duchenne muscular dystrophy were added, while the same two references were removed but replaced with online-ahead-of-print identifiers—resulting in a minor bibliographic update rather than a substantive page content change.SummaryDifference0.7%

Stay in the know with updates to Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of PF-06939926 Gene Therapy in Duchenne Clinical Trial page.